Aveanna (AVAH) 10% Owner J.H. Whitney Sells Shares

What Happened
J.H. Whitney Equity Partners VII (reported as a 10% owner) and affiliated stockholder entities sold a total of 14,746,077 shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 per share. The transactions occurred as part of an underwritten secondary offering (including the exercise of the underwriter’s option) and generated approximately $169,579,886 in proceeds. Breakdown by seller and date:

• J.H. Whitney VII, L.P.: 10,112,125 shares sold on Aug 20, 2026 — $116,289,438. (F2)
• PSA Healthcare Investment Holding LLC: 957,918 shares sold on Aug 20, 2026 — $11,016,057. (F3)
• PSA Iliad Holdings LLC: 1,426,034 shares sold on Aug 20, 2026 — $16,399,391. (F4)
• PSA Healthcare Investment Holding LLC: 2,250,000 shares sold on Aug 21, 2026 pursuant to the underwriter’s option — $25,875,000. (F5)

Key Details

• Transaction dates and price: Aug 20–21, 2026 at $11.50 per share.
• Total shares sold: 14,746,077; total proceeds: ~$169.58 million.
• Shares owned after transaction: Not specified in the filing.
• Filing date: Form 4 filed Aug 24, 2026 — 3–4 days after the trades, which appears to exceed the typical 2-business-day Form 4 deadline.
• Notable footnotes: The filing explains the sellers are related entities under common control (Equity Partners VII, JHW VII, Strategic Partners VII, PSA Healthcare, PSA Iliad), and the sales were made in an underwritten secondary offering (including exercise of the underwriter’s option). Each entity disclaims beneficial ownership except to the extent of pecuniary interest. (F1–F5)

Context
These were institutional sales conducted through an underwritten secondary offering — not open-market trades by a company executive. For retail investors, that means the activity reflects a structured capital markets transaction by related investment entities rather than an individual insider's private decision. Sales by large shareholders are common during secondary offerings and do not, by themselves, indicate management sentiment about the company’s prospects.